Clinical trial · Observational
Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions
NCT00527891CI-TRIAL-00007652completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary Objective: 1\. To compare the efficacy of 1.5T vs. 3T T1 and T2-weighted MR images sequences for the detection and evaluation of liver lesions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Signa Excite 3.0 T MRI Scan | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Signa Excite 3.0 T MRI Scan
- description
- Signa Excite 3.0 T MRI Scan
- interventionNames
- Procedure: Signa Excite 3.0 T MRI Scan
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients with a liver lesion larger than 1cm detected by a prior imaging modality. 2. Patients have been scheduled and are eligible for an MRI of the abdomen or MRI of the liver or MRI of the kidney examination. Exclusion Criteria: 1\) Patients who are unable to cooperate with breath hold.
References
Publications (0)
Data not yet available
No reference posted for this study.